(Reuters) - Drugmaker Allergan Plc (N:AGN) said it expected revenue to be greater than $8 billion in the second half to reflect the divesture of its global generics business to Teva Pharmaceuticals Industries Ltd (TA:TEVA) (N:TEVA).
The company said it intends to report its global generics business as discontinued operations in the third quarter.